开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Shivkumar Chella
Lung cancer, a leading cause of cancer-related mortality, is characterized by its heterogeneity and resistance to therapy. Emerging research has revealed the pivotal role of lung cancer stem cells (CSCs) in driving tumorigenesis, metastasis, therapy resistance, and disease relapse. This article provides a comprehensive review of the molecular features of lung CSCs, including their identification, regulatory pathways, and interactions within the tumor microenvironment [1]. Moreover, the discussion explores potential therapeutic targets for lung CSCs, considering strategies to disrupt their self-renewal, enhance susceptibility to treatment, and improve patient outcomes. Understanding the intricate biology of lung CSCs and their vulnerabilities offers insights into the development of novel therapies to address the challenges posed by lung cancer [2, 3].